GlassScriptPhysician profile
Martin B Langford
NPI 1992729826
$15,479.43
in general payments reported to CMS, 2019-2025
84 companies · $3,140 in 2025
The $3,140 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,912 · 2020: $671 · 2021: $373 · 2022: $1,615 · 2023: $3,217 · 2024: $3,552 · 2025: $3,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,727 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,726.63 |
| Education | $181.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,067.23 | 2019-2025 | |
| Pfizer INC. | $949.85 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $852.33 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $789.15 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $747.61 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $689.91 | 2021-2025 | Reblozyl, Opdualag, Opdivo |
| Genentech USA, INC. | $672.70 | 2019-2025 | Phesgo, Polivy, Venclexta |
| Incyte Corporation | $607.60 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $513.62 | 2019-2025 | Datroway, Imfinzi |
| Amgen INC. | $412.09 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Genzyme Corporation | $387.01 | 2019-2025 | |
| Abbvie INC. | $365.08 | 2019-2025 | |
| Exelixis INC. | $357.87 | 2019-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $350.40 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $348.64 | 2019-2025 | Enhertu, Datroway, Injectafer |
Show all 84 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Langford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.